According to Seeking Alpha data: Regeneron's capital structure is relatively robust with a small debt figure relative to its market capitalization, and a significant cash position.

Source: https://seekingalpha.com/article/4629764-regeneron-gets-boost-with-fda-approval-of-high-dose-eylea-rating-upgrade?source=feed_all_articles

Importantly, these anticipated incremental expenses will be reimbursed by Sanofi, generally resulting in a neutral impact to Regeneron's 2023 operating profit.

Source: https://seekingalpha.com/article/4600062-regeneron-pharmaceuticals-inc-regn-q1-2023-earnings-call-transcript?source=feed_all_articles